частота побочного действия на в/в железо была выше у венофера и железа-декстрана, чем у феринжекта или монофера, переход на альтернативный препарат в таком случае предпочтительнее, чем введение прежнего под лек. прикрытием:
Rate of infusion events differed among iron formulations:
4.3% (n = 970; 95% CI, 4.1%-4.6%) iron sucrose,
3.8% (n = 345, 95% CI: 3.4%-4.2%) iron dextran (test and full doses or test dose alone),
1.8% (n = 57; 95% CI, 1.4%-2.3%) ferumoxytol, and
1.4% (n = 17, 95% CI, 0.8%-2.3%) ferric carboxymaltose (P < .001).
Severe adverse events were exceedingly rare with only 2 documented epinephrine administrations, both associated with iron dextran.
Incidence of adverse events among those who received premedication was 23-fold higher compared with those who did not (38.6% vs 1.7% P < .001).
Among 873 patients with history of infusion reaction who underwent readministration, the majority received the same formulation, which was associated with significantly higher reaction rate particularly if premedication was administered (68% [95% CI, 64%-72%] vs 32% [95% CI, 26%-41%], respectively), compared with those who received an alternate formulation (21% [95% CI, 11%-35%] vs 5% [95% CI, 2%-12%], respectively) (P < .001).
---
JAMA Netw Open. 2022 Mar 1;5(3):e224488.
Analysis of Adverse Events and Intravenous Iron Infusion Formulations in Adults With and Without Prior Infusion Reactions
|